Trajan Wealth LLC Takes $9.11 Million Position in Kenvue Inc. $KVUE

Trajan Wealth LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 476,912 shares of the company’s stock, valued at approximately $9,114,000.

Other institutional investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership purchased a new position in Kenvue during the second quarter valued at $6,528,000. Jump Financial LLC grew its holdings in Kenvue by 210.6% during the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock valued at $1,147,000 after purchasing an additional 37,170 shares during the period. AXA S.A. increased its position in Kenvue by 21.1% in the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after buying an additional 8,524 shares in the last quarter. NewEdge Advisors LLC increased its position in Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock worth $2,040,000 after buying an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after buying an additional 10,885 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

NYSE:KVUE opened at $19.41 on Tuesday. The business’s 50-day simple moving average is $19.08 and its two-hundred day simple moving average is $18.21. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $21.63. The stock has a market cap of $37.27 billion, a PE ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.29 EPS. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. Kenvue’s payout ratio is 96.55%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of analyst reports. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Finally, Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.